Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8065528 | 1.00 | PGR (0.42) | PGRARLMNAALDH1A1HPGD | |
| SCHEMBL20029627 | 0.81 | PGR (0.33) | PGRARLMNAALDH1A1HPGD | |
| SCHEMBL25075754 | 0.81 | PGR (0.33) | PGRARLMNAALDH1A1HPGD | |
| SCHEMBL25075656 | 0.81 | PGR (0.33) | PGRARLMNAALDH1A1HPGD | |
| SCHEMBL25076171 | 0.79 | CRBN (0.33) | PGRAR | |
| SCHEMBL23965444 | 0.78 | IDO1 (0.32) | PGRAR | |
| SCHEMBL21245197 | 0.78 | MEN1 (0.32) | PGRARCYP2C19 | |
| SCHEMBL23836084 | 0.78 | PGR (0.32) | PGRAR | |
| SCHEMBL22982351 | 0.78 | MEN1 (0.32) | PGRARCYP2C19 | |
| SCHEMBL26460144 | 0.78 | PGR (0.34) | PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241045-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-20230159535-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-11517564-B2 | Methods of treatment for cystic fibrosis | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-12-06 | — | — | US | disclosed |
| US-20200138798-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200138798-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, SLC26A4, SCNN1B | PGR 4327/4885AR 4641/4885LMNA 2656/4885 |
| US-20230241045-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, SLC26A4, SCNN1B | PGR 4567/4885AR 4666/4885LMNA 2504/4885 |
| US-11517564-B2 | Methods of treatment for cystic fibrosis | CFTR, SLC26A4, SCNN1B | PGR 4327/4885AR 4641/4885LMNA 2656/4885 |
| US-20230159535-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | PGR 636/4885AR 1387/4885LMNA 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.